CONTEXT: Data on the potential effect of metformin on the risk of liver cancer are limited and inconsistent. OBJECTIVE: The objective of this study was to review the evidence currently available to examine the potential role of metformin in chemoprevention for liver cancer in patients with type 2 diabetes. DATA SOURCES: The data sources of the study included the PubMed and SciVerse Scopus databases. STUDY SELECTION: Selection included studies that assessed the effect of metformin therapy on the risk of liver cancer in patients with type 2 diabetes. DATA EXTRACTION: Summary effect estimates were derived using a random-effects meta-analysis model. DATA SYNTHESIS: A database was developed on the basis of five studies consisting of approximately 105,495 patients with type 2 diabetes. In meta-analyses, metformin was associated with an estimated 62% reduction in the risk of liver cancer among patients with type 2 diabetes (odds ratio 0.38, 95% confidence interval 0.24, 0.59; P < 0.001). The effect estimates were heterogeneous across the five included studies (P for heterogeneity = 0.001; I(2) = 78%). When restricting the analysis to the four studies related to hepatocellular carcinoma, metformin was again associated with a significantly lower cancer risk (odds ratio 0.30, 95% confidence interval 0.17, 0.52; P < 0.001), and there was evidence of significant heterogeneity between these four studies (P for heterogeneity = 0.03; I(2) = 67%). CONCLUSIONS: Metformin appears to be associated with a lower risk of liver cancer in patients with type 2 diabetes. Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is needed.
CONTEXT: Data on the potential effect of metformin on the risk of liver cancer are limited and inconsistent. OBJECTIVE: The objective of this study was to review the evidence currently available to examine the potential role of metformin in chemoprevention for liver cancer in patients with type 2 diabetes. DATA SOURCES: The data sources of the study included the PubMed and SciVerse Scopus databases. STUDY SELECTION: Selection included studies that assessed the effect of metformin therapy on the risk of liver cancer in patients with type 2 diabetes. DATA EXTRACTION: Summary effect estimates were derived using a random-effects meta-analysis model. DATA SYNTHESIS: A database was developed on the basis of five studies consisting of approximately 105,495 patients with type 2 diabetes. In meta-analyses, metformin was associated with an estimated 62% reduction in the risk of liver cancer among patients with type 2 diabetes (odds ratio 0.38, 95% confidence interval 0.24, 0.59; P < 0.001). The effect estimates were heterogeneous across the five included studies (P for heterogeneity = 0.001; I(2) = 78%). When restricting the analysis to the four studies related to hepatocellular carcinoma, metformin was again associated with a significantly lower cancer risk (odds ratio 0.30, 95% confidence interval 0.17, 0.52; P < 0.001), and there was evidence of significant heterogeneity between these four studies (P for heterogeneity = 0.03; I(2) = 67%). CONCLUSIONS:Metformin appears to be associated with a lower risk of liver cancer in patients with type 2 diabetes. Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is needed.
Authors: Danielle K DePeralta; Lan Wei; Sarani Ghoshal; Benjamin Schmidt; Gregory Y Lauwers; Michael Lanuti; Raymond T Chung; Kenneth K Tanabe; Bryan C Fuchs Journal: Cancer Date: 2016-02-23 Impact factor: 6.860
Authors: Ewa Klara Stuermer; M Besser; N Terberger; V Koester; H S Bachmann; A L Severing Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-12-07 Impact factor: 3.000
Authors: Harvey J Murff; Christianne L Roumie; Robert A Greevy; Amber J Hackstadt; Lucy E D'Agostino McGowan; Adriana M Hung; Carlos G Grijalva; Marie R Griffin Journal: Cancer Causes Control Date: 2018-07-18 Impact factor: 2.506
Authors: Mary E Rinella; Zurabi Lominadze; Rohit Loomba; Michael Charlton; Brent A Neuschwander-Tetri; Stephen H Caldwell; Kris Kowdley; Stephen A Harrison Journal: Therap Adv Gastroenterol Date: 2016-01 Impact factor: 4.409